Previous 10 | Next 10 |
Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.27 (vs. -$0.25 last year) and the consensus Revenue Estimate is $28.82M (+23.2% Y/Y). Over the last 1 year, AUPH ...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, will give a corporate presentation at the upcoming investor healthcare conference. Oppenheimer 33rd Annual Virtual Healthcare Conference being he...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for fourth quarter and full year 2023 on Tuesday, February 28, 2023, before markets open. Aurinia’s management team will host a conference call/webcas...
Summary Vera Therapeutics has released an updated interim PP analysis on the phase 2b ORIGIN trial. The updated data excluded 14 patients who had some degree of a trial protocol violation, further enriching the data. The PP data was better than ITT data, where 36 weeks of data of th...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia) announces that the Patent Trial and Appeal Board (PTAB) of the United States’ Patent and Trademark Office has terminated the Inter Partes Review (IPR) it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036. ...
Canadian biotech Aurinia Pharmaceuticals ( NASDAQ: AUPH ) jumped ~11% pre-market Wednesday after announcing that the company is on track to receive two new patents in the U.S. and EU covering its lupus nephritis therapy Lupkynis. The U.S. patent relates to the dosing regimen of Lu...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Appl...
Summary Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD. The latest clinical trials on Ensifentrine u...
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were up by 79.6% this week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence . The biopharmaceutical company, which specializes in treating autoimmune disorders, closed las...
Aurinia Pharmaceuticals ( NASDAQ: AUPH ) has reported prelim net revenue of ~$28.4M for fourth quarter compared to consensus estimate of $27.13M. For the three months ended Dec. 31, 2022, preliminary unaudited net revenues included net product revenues of ~$28.3M and license a...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...